Targeting gene therapy for prostate cancer cells by liposomes complexed with anti-prostate-specific membrane antigen monoclonal antibody

Human Gene Therapy

Volumn 17, Issue 10, 2006, Pages 997-1005

  Ikegami, Shusei ^a   Yamakami, Kazuo ^a   Ono, Takeshi ^a   Sato, Masaki ^a   Suzuki, Satoshi ^a   Yoshimura, Ichiro ^a   Asano, Tomohiko ^a   Hayakawa, Masamichi ^a   Tadakuma, Takushi ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 BROMO 4 CHLORO 3 INDOYL BETA DEXTRO GALACTOPYRANOSIDE; GANCICLOVIR; IMMUNOGLOBULIN G; LUCIFERASE; MLN 591; MONOCLONAL ANTIBODY; PLASMID DNA; POLYLYSINE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN MONOCLONAL ANTIBODY; PYRANOSIDE; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL STRAIN LNCAP; COMPLEX FORMATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG SYNTHESIS; GENE THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; MOUSE; NONHUMAN; PROSTATE CANCER; SUICIDE GENE; SUICIDE GENE THERAPY; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL PROLIFERATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, TRANSGENIC, SUICIDE; HUMANS; LIPOSOMES; MALE; MICE; MICE, NUDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 33846154977     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.997     Document Type: Article

References (29)

1. ARANGOA, M.A., DUZGUNES, N., and TROS DE LLARDUYA, C. (2003). Increased receptor-mediated gene delivery to the liver by protamine-enhanced asialofetuin-lipoplexes. Gene Ther. 10, 5-14.
2. BANDER, N.H., NANUS, D.M., MILOWSKY, M.I., KOSTAKOGLU, L., VALLABAHAJOSULA, S., and GOLDSMITH, S.J. (2003). Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin. Oncol. 30, 667-676.
3. BOCCI, G., MAN, S., GREEN, S.K., FRANCIA, G., EBOS, J.M., DU MANOIR, J.M., WEINERMAN, A., EMMENEGGER, U., MA, L., THORPE, P., DAVIDOFF, A., HUBER, J., HICKLIN, D.J., and KERBEL, R.S. (2004). Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res. 64, 6616-6625.
4. BOSTWICK, D.G., PACELLI, A., BLUTE, M., ROCHE, P., and MURPHY, G.P. (1998). Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 82, 2256-2261.
5. CHANG, S.S., O'KEEF, D.S., BACICH, D.J., REUTER, V.E., HESTON, W.D.W., and GAUDIN, P.B. (1999). Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin. Cancer Res. 5, 2674-2681.
6. GLEAVE, M., HSIEH, J.T., GAO, C., VON ESCHENBACH, A.C., and CHUNG, L.W.K. (1991). Acceleration of human prostate carcinoma growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res. 51, 3753-3761.
7. HENRY, M.D., WEN, S., SILVA, M.D., CHANDRA, S., MILTON, M., and WORLAND P.J. (2004). A prostate-specific membrane antigen-targeted monoclonal antibody: Chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. 64, 7995-8001.
8. HUWYLER, J., YANG, J., and PARDRIDGE, W.M. (1997). Receptor mediated delivery of daunomycin using immunoliposomes: Pharmacokinetics and tissue distribution in the rat. J. Pharmacol. Exp. Ther. 282, 1541-1546.
9. IKEGAMI, S., TADAKUMA, T., SUZUKI, S., YOSHIMURA, I., ASANO, T., and HAYAKAWA, M. (2002). Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre recombinase/LoxP system for prostate cancer cells under androgen ablation condition. Jpn. J. Cancer Res. 93, 1154-1163.
10. IKEGAMI, S., TADAKUMA, T., ONO, T., SUZUKI, S., YOSHIMURA, I., ASANO, T., and HAYAKAWA, M. (2004). Treatment efficiency suicide gene therapy using prostate-specific membrane antigen promoter/enhancer in a castrated mouse model of prostate cancer. Cancer Sci. 95, 367-370.
11. ISRAELI, R.S., POWELL, C.T., FAIR, W.R., and HESTON, W.D.W. (1993). Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 53, 227-230.
12. ISRAELI, R.S., POWELL, C.T., CORR, J.G., FAIR, W.R., and HESTON, W.D.W. (1994). Expression of the prostate-specific membrane antigen. Cancer Res. 54, 1807-1811.
13. KAWASAKI, M., and NAKAYAMA, J. (1997). Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 57, 2321-2324.
14. KURANE, S., KRAUSS, J.C., WATARI, E., KANNAGI, R., CHANG, A.E., and KUDOH, S. (1998). Targeted gene transfer for adenocarcinoma using a combination of tumor-specific antibody and tissue-specific promoter. Jpn. J. Cancer Res. 89, 1212-1219.
15. LEONARD, J.P., COLEMAN, M., KETAS, J.C., CHADBURN, A., FURMAN, R., SCHUSTER, M.W., FELDMAN, E.J., ASHE, M., SCHUSTER, S.J., WEGENER, W.A., HANSEN, H.J., ZICCARDI, H., ESCHENBERG, M., GAYKO, U., FIELDS, S.Z., CESANO, A., and GOLDENBERG D.M. (2004). Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results. Clin. Cancer Res. 10, 5327-5334.
16. LIU, H., MOY, P., KIM, S., XIA, Y., RAJASEKARAN, A., NAVARRO, V. KNUDSEN, B., and BANDER, N.H. (1997). Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 57, 3629-3634.
17. MAEDA, H., WU, J., SAWA, T., MATSUMURA, Y., and HORI, K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control. Release 65, 271-284.
18. MATAR, P., ROJO, F., CASSIA, R., MORENO-BUENO, G., DI COSIMO, S., TABERNERO, J., GUZMAN, M., RODRIGUEZ, S., ARRIBAS, J., PALASIOS, J., and BASELAGA, J. (2004). Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin. Cancer Res. 10, 6487-501.
19. MILOWSKY, M.I., MANUS, D.M., KOSTAKOGLU, L., VALLABHAJOSULA, S., GOLDSMITH S.J., and BANDER, N.H. (2004). Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J. Clin. Oncol. 22, 2522-2531.
20. NANUS, D.M., MILOWSKY, M.I., KOSTAKOGLU, L., SMITH-JONES, P.M., VALLABAHAJOSULA, S., GOLDSMITH, S.J., and BANDER, N.H. (2003). Clinical use of monoclonal antibody HuJ591 therapy: Targeting prostate specific membrane antigen. J. Urol. 170, S84-S89.
21. RENSEN, P.C., DE VRUEH, R.L., KUIPER, J., BIJSTERBOSCH, M.K., BIESSEN, E.A., and VAN BERKEL, T.J. (2001). Recombinant lipoproteins: Lipoprotein-like lipid particles for drug targeting. Adv. Drug Deliv. Rev. 47, 251-276.
22. SMITH-JONES, P.M., VALLABHAJOSULA, S., NAVARRO, V., BASTIDAS, D., GOLDSMITH, S.J., and BANDER, N.H. (2003). Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor. J. Nucl. Med. 44, 610-617.
23. SUZUKI, S., TADAKUMA, T., KUNITOMI, M., TAKAYAMA, E., SATO, M., ASANO, T., NAKAMURA, H., and HAYAKAWA, M. (2001a). Liposome-mediated gene therapy using HSV-TK/ganciclovir under the control of human PSA promoter in prostate cancer cells. Urol. Int. 67, 216-223.
24. SUZUKI, S., TADAKUMA, T., ASANO, T., and HAYAKAWA, M. (2001b). Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations. Cancer Res. 61, 1276-1279.
25. VALLABHAJOSULA, S., SMITH-JONES, P.M., NAVARRO, V., GOLDSMITH S.J., and BANDER, N.H. (2004). Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice. Prostate 58, 145-155.
26. WAGNER, E., ZENKE, M., COTTON, M., BEUG, H., and BIRNSTIEL, M.L. (1990). Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc. Natl. Acad. Sci. U.S.A. 87, 3410-3414.
27. WAGNER, E., COTTON, M., FOISNER, R., and BIRNSTIEL, M.L. (1991). Transferrin-polycation-DNA complexes: The effect of polycations of structure of the complex and DNA delivery to cells. Proc. Natl. Acad. Sci. U.S.A. 88, 4255-4259.
28. WRIGHT, G.L., Jr., GROB, B.M., HALEY, C., GROSSMAN, K., NEWHALL, K., PETRYLAK, D., TROYER, J., KONCHUBA, A., SCHELLHAMMER, P.F., and MORIARTY, R. (1996). Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48, 326-334.
29. YUAN, F., LEUNIG, M., HUANG S.K., BERK, D.A., PAPAHADJOPOULOS, D., and JAIN, R.K. (1994). Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54, 3352-3356.